



MARKET RELEASE

14 May 2015

Antisense Therapeutics Limited

TRADING HALT

The securities of Antisense Therapeutics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 18 May 2015 or when the announcement is released to the market.

Security Code: ANP

Kate Kidson

Principal Adviser, Listings Compliance (Melbourne)

Thursday 14 May 2015

Kate Kidson
Principal Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited

Email: kate.kidson@asx.com.au

Dear Kate,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested pending an announcement in relation to the out licensing of ATL1103;
- Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the earlier of the release of an announcement to the market or the morning of Monday 18 May 2015; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary